206 related articles for article (PubMed ID: 11120945)
1. Role of human immunodeficiency virus (HIV) type 1 envelope in the anti-HIV activity of the betulinic acid derivative IC9564.
Holz-Smith SL; Sun IC; Jin L; Matthews TJ; Lee KH; Chen CH
Antimicrob Agents Chemother; 2001 Jan; 45(1):60-6. PubMed ID: 11120945
[TBL] [Abstract][Full Text] [Related]
2. Betulinic acid derivatives that target gp120 and inhibit multiple genetic subtypes of human immunodeficiency virus type 1.
Lai W; Huang L; Ho P; Li Z; Montefiori D; Chen CH
Antimicrob Agents Chemother; 2008 Jan; 52(1):128-36. PubMed ID: 17954689
[TBL] [Abstract][Full Text] [Related]
3. Anti-AIDS agents 49. Synthesis, anti-HIV, and anti-fusion activities of IC9564 analogues based on betulinic acid.
Sun IC; Chen CH; Kashiwada Y; Wu JH; Wang HK; Lee KH
J Med Chem; 2002 Sep; 45(19):4271-5. PubMed ID: 12213068
[TBL] [Abstract][Full Text] [Related]
4. Conformation of gp120 determines the sensitivity of HIV-1 DH012 to the entry inhibitor IC9564.
Yuan X; Huang L; Ho P; Labranche C; Chen CH
Virology; 2004 Jul; 324(2):525-30. PubMed ID: 15207637
[TBL] [Abstract][Full Text] [Related]
5. Resistance to a drug blocking human immunodeficiency virus type 1 entry (RPR103611) is conferred by mutations in gp41.
Labrosse B; Pleskoff O; Sol N; Jones C; Hénin Y; Alizon M
J Virol; 1997 Nov; 71(11):8230-6. PubMed ID: 9343174
[TBL] [Abstract][Full Text] [Related]
6. Induction of a nonproductive conformational change in gp120 by a small molecule HIV type 1 entry inhibitor.
Huang L; Lai W; Ho P; Chen CH
AIDS Res Hum Retroviruses; 2007 Jan; 23(1):28-32. PubMed ID: 17263629
[TBL] [Abstract][Full Text] [Related]
7. Bifunctional anti-human immunodeficiency virus type 1 small molecules with two novel mechanisms of action.
Huang L; Yuan X; Aiken C; Chen CH
Antimicrob Agents Chemother; 2004 Feb; 48(2):663-5. PubMed ID: 14742233
[TBL] [Abstract][Full Text] [Related]
8. Role of the ectodomain of the gp41 transmembrane envelope protein of human immunodeficiency virus type 1 in late steps of the membrane fusion process.
Bär S; Alizon M
J Virol; 2004 Jan; 78(2):811-20. PubMed ID: 14694113
[TBL] [Abstract][Full Text] [Related]
9. Sensitivity to a nonpeptidic compound (RPR103611) blocking human immunodeficiency virus type 1 Env-mediated fusion depends on sequence and accessibility of the gp41 loop region.
Labrosse B; Treboute C; Alizon M
J Virol; 2000 Mar; 74(5):2142-50. PubMed ID: 10666243
[TBL] [Abstract][Full Text] [Related]
10. Sensitivity of human immunodeficiency virus type 1 to the fusion inhibitor T-20 is modulated by coreceptor specificity defined by the V3 loop of gp120.
Derdeyn CA; Decker JM; Sfakianos JN; Wu X; O'Brien WA; Ratner L; Kappes JC; Shaw GM; Hunter E
J Virol; 2000 Sep; 74(18):8358-67. PubMed ID: 10954535
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and anti-HIV activity of bi-functional betulinic acid derivatives.
Huang L; Ho P; Lee KH; Chen CH
Bioorg Med Chem; 2006 Apr; 14(7):2279-89. PubMed ID: 16314103
[TBL] [Abstract][Full Text] [Related]
12. Different from the HIV fusion inhibitor C34, the anti-HIV drug Fuzeon (T-20) inhibits HIV-1 entry by targeting multiple sites in gp41 and gp120.
Liu S; Lu H; Niu J; Xu Y; Wu S; Jiang S
J Biol Chem; 2005 Mar; 280(12):11259-73. PubMed ID: 15640162
[TBL] [Abstract][Full Text] [Related]
13. Sensitivity of human immunodeficiency virus type 1 to fusion inhibitors targeted to the gp41 first heptad repeat involves distinct regions of gp41 and is consistently modulated by gp120 interactions with the coreceptor.
Derdeyn CA; Decker JM; Sfakianos JN; Zhang Z; O'Brien WA; Ratner L; Shaw GM; Hunter E
J Virol; 2001 Sep; 75(18):8605-14. PubMed ID: 11507206
[TBL] [Abstract][Full Text] [Related]
14. The anti-HIV activity of ADS-J1 targets the HIV-1 gp120.
Armand-Ugón M; Clotet-Codina I; Tintori C; Manetti F; Clotet B; Botta M; Esté JA
Virology; 2005 Dec; 343(1):141-9. PubMed ID: 16168454
[TBL] [Abstract][Full Text] [Related]
15. Anti-human immunodeficiency virus activity of YK-FH312 (a betulinic acid derivative), a novel compound blocking viral maturation.
Kanamoto T; Kashiwada Y; Kanbara K; Gotoh K; Yoshimori M; Goto T; Sano K; Nakashima H
Antimicrob Agents Chemother; 2001 Apr; 45(4):1225-30. PubMed ID: 11257038
[TBL] [Abstract][Full Text] [Related]
16. Development of resistance of human immunodeficiency virus type 1 to dextran sulfate associated with the emergence of specific mutations in the envelope gp120 glycoprotein.
Este JA; Schols D; De Vreese K; Van Laethem K; Vandamme AM; Desmyter J; De Clercq E
Mol Pharmacol; 1997 Jul; 52(1):98-104. PubMed ID: 9224818
[TBL] [Abstract][Full Text] [Related]
17. The molecular target of bicyclams, potent inhibitors of human immunodeficiency virus replication.
de Vreese K; Kofler-Mongold V; Leutgeb C; Weber V; Vermeire K; Schacht S; Anné J; de Clercq E; Datema R; Werner G
J Virol; 1996 Feb; 70(2):689-96. PubMed ID: 8551604
[TBL] [Abstract][Full Text] [Related]
18. Development of resistance to VIR-353 with cross-resistance to the natural HIV-1 entry virus inhibitory peptide (VIRIP).
Gonzalez E; Ballana E; Clotet B; Esté JA
AIDS; 2011 Aug; 25(13):1557-83. PubMed ID: 21572303
[TBL] [Abstract][Full Text] [Related]
19. Mutations That Increase the Stability of the Postfusion gp41 Conformation of the HIV-1 Envelope Glycoprotein Are Selected by both an X4 and R5 HIV-1 Virus To Escape Fusion Inhibitors Corresponding to Heptad Repeat 1 of gp41, but the gp120 Adaptive Mutations Differ between the Two Viruses.
Zhuang M; Vassell R; Yuan C; Keller PW; Ling H; Wang W; Weiss CD
J Virol; 2019 Jun; 93(11):. PubMed ID: 30894471
[TBL] [Abstract][Full Text] [Related]
20. Pradimicin S, a highly soluble nonpeptidic small-size carbohydrate-binding antibiotic, is an anti-HIV drug lead for both microbicidal and systemic use.
Balzarini J; François KO; Van Laethem K; Hoorelbeke B; Renders M; Auwerx J; Liekens S; Oki T; Igarashi Y; Schols D
Antimicrob Agents Chemother; 2010 Apr; 54(4):1425-35. PubMed ID: 20047920
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
